Drug intelligence / Profile preview

RDH091

Development stage: Preclinical
Lead developer: Apichope Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

RDH091 is a small molecule drug candidate developed by Apichope Pharmaceutical (Guangzhou Apichope Pharmaceutical Co., Ltd.) for the treatment of cardiovascular and cerebrovascular diseases. It is designed as an oral extended-release tablet, utilizing the company's expertise in controlled-release formulation technologies. As a 'Class 2' improved new drug in the Chinese regulatory context, RDH091 likely represents an optimized version of an existing therapeutic agent, aimed at providing more stable plasma concentrations and improving patient adherence. The candidate is currently in the preclinical stage of development, and its specific biological target remains proprietary.

Other names: RDH091 extended-release tabletRDH-091 extended-release tabletRDH 091 extended-release tablet

Beyond the preview

Go deeper on RDH091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RDH091.

Explore the full profile